Vanda Pharma Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatits
March 04, 2015 at 16:33 PM EST
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced top-line results of the Phase II proof of concept clinical study ...
